Pay in 4 interest-free payments of $6.72 Learn more
Ships within 48 hours · Estimated delivery Aug 7 - Aug 12
Weight loss outcomes associated with semaglutide treatment for patients with overweight or obesity
A large-scale observational study found that diabetic patients taking GLP-1 drugs had a 67% reduced risk of developing Alzheimers compared to those not on the medication, highlighting a powerful potential for neuroprotection
A strong dose-response relation between serum concentrations of persistent organic pollutants and diabetes: results from the National Health and Examination Survey 1999-2002
Eli Lilly (NYSE: LLY) saw its shares climb 5% this past week after announcing that its history-making oral obesity candidate, orforglipron aced the Phase III ATTAIN-2 trial (NCT05872620), which assessed the small molecule glucagon-like peptide-1 (GLP-1) receptor agonist in adults who were obese or overweight and had type 2 diabetes
US$ 21.83
US$ 25.12
US$ 27.11
US$ 22.96
